Zynex (NASDAQ:ZYXI) Updates FY24 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $0.20 for the period, compared to the consensus earnings per share estimate of $0.51. The company issued revenue guidance of $200.0 million, compared to the consensus revenue estimate of $226.95 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Zynex Trading Down 12.4 %

NASDAQ ZYXI traded down $1.26 during trading on Friday, hitting $8.93. The stock had a trading volume of 1,034,596 shares, compared to its average volume of 195,244. The company has a market capitalization of $283.75 million, a PE ratio of 38.83 and a beta of 0.53. The company has a quick ratio of 2.87, a current ratio of 3.58 and a debt-to-equity ratio of 1.76. The firm has a 50 day moving average price of $9.55 and a 200 day moving average price of $11.06. Zynex has a twelve month low of $6.88 and a twelve month high of $13.77.

Zynex (NASDAQ:ZYXI) last released its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $49.88 million during the quarter, compared to analyst estimates of $51.99 million. Zynex had a net margin of 4.33% and a return on equity of 16.34%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. As a group, equities research analysts forecast that Zynex will post 0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZYXI. Royal Bank of Canada lowered their price objective on Zynex from $15.00 to $12.00 and set an outperform rating for the company in a research report on Friday. HC Wainwright lowered their price objective on Zynex from $21.00 to $16.00 and set a buy rating for the company in a research report on Friday.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.